Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2917051 | 0.84 | PTGS1 (0.56) | PTGS1PTGS2KMT2AMEN1MT-CO2 | |
| SCHEMBL28499999 | 0.84 | PTGS2 (0.56) | PTGS1PTGS2KMT2AMEN1MT-CO2 | |
| SCHEMBL27557372 | 0.83 | PTGS1 (0.40) | PTGS1PTGS2KMT2AMEN1HPGD | |
| SCHEMBL9651355 | 0.83 | PTGS1 (0.62) | PTGS1PTGS2KMT2AMEN1MT-CO2 | |
| SCHEMBL28370252 | 0.83 | PTGS1 (0.55) | PTGS1PTGS2KMT2AMEN1MT-CO2 | |
| SCHEMBL7716661 | 0.82 | KMT2A (0.46) | KMT2AMEN1PPARGMAPTL3MBTL1 | |
| SCHEMBL1345676 | 0.80 | CXCR1 (0.47) | PTGS1PTGS2MT-CO2HPGDTSHR | |
| SCHEMBL7619765 | 0.80 | CXCR1 (0.47) | PTGS1PTGS2MT-CO2HPGDTSHR | |
| SCHEMBL8590234 | 0.80 | PTGS1 (0.51) | PTGS1PTGS2KMT2AMEN1MT-CO2 | |
| SCHEMBL16364505 | 0.79 | PTGS1 (0.60) | PTGS1PTGS2KMT2AMEN1MT-CO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| EP-0315399-B1 | Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same | RHONE POULENC RORER INT (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |